In recent years AD has been increasingly viewed as a metabolic disorder, exhibiting impaired brain responses to glucose and insulin, with increased insulin and insulin-like growth factor (IGF) resistance (Talbot et al., 2012; Ishii et al., 2014). This evidence concerns the gene INS and metabolic disease.